REFRACTORY MULTIPLE MYELOMA

This study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to see how many patients' tumors shrink or disappear.…

This early-phase trial tests whether adding an experimental drug called SX-682 to standard cancer drugs is safe for people with multiple myeloma that has come back or not responded to prior therapy. SX-682 works by blocking signals that suppress the immune system, potentially hel…

This study tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if the combination is safe and helps control the cancer. About 62 adults who h…

This early-phase trial tests a combination of two drugs—iberdomide and teclistamab—in people with multiple myeloma that has come back or stopped responding to at least four prior treatments. The goal is to find the safest and most effective dose of iberdomide when used with tecli…

This study tests whether the drug elranatamab, given after CAR T-cell therapy (idecabtagene vicleucel), can lower the chance of multiple myeloma worsening. About 32 adults with relapsed or treatment-resistant myeloma will take part. The goal is to see if this combination helps mo…

This early-phase study tests whether a personalized cancer vaccine (made by fusing a patient's own immune cells with their tumor cells) combined with the drug elranatamab is safe and works for people with multiple myeloma that has come back or stopped responding to prior treatmen…

This study tests a drug called elranatamab in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if giving the drug in an outpatient setting with breaks between doses can reduce side effects and hospital st…

This early-phase study tests a new drug called OPN-6602, given alone or with another drug (dexamethasone), in people whose multiple myeloma has returned or stopped responding to at least three prior treatments. The main goal is to check the drug's safety and find the right dose. …

This study tests whether adding two drugs, dasatinib and quercetin, to standard CAR-T cell therapy can improve outcomes for people with multiple myeloma that has returned or not responded to prior treatments. About 44 adults who have tried at least three other therapies will rece…

This early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy is safe and effective for people with multiple myeloma that has returned or not responded to treatment. About 25 adults will receive the vaccine along with CAR-…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has returned or stopped responding to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and atta…

This study tests whether reducing the dose of the drug linvoseltamab, based on how well a patient responds early on, is safe and effective for people with multiple myeloma that has come back or stopped responding to other treatments. Linvoseltamab helps the immune system attack c…

This study tests whether a combination of elotuzumab, iberdomide, and dexamethasone can help control multiple myeloma that has returned or not responded to treatment, after patients have already received a CAR-T cell therapy called idecabtagene vicleucel. About 49 adults with rel…

This study tests a new combination of four drugs (iberdomide, daratumumab, carfilzomib, and dexamethasone) in 30 people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if this combo can shrink the cancer and keep it from coming ba…

This early-phase trial tests a new treatment for multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified in the lab with CRISPR gene editing to target and attack cancer cells. About 30 adults will …

This study tests a combination of three drugs—talquetamab, iberdomide, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to other treatments. The goal is to find the safest dose and check for side effects. About 32 adults will take part in …

This study is for people with multiple myeloma that has returned or not responded to at least three prior treatments. It tests different doses and schedules of a drug called belantamab mafodotin, which targets and kills cancer cells. The goal is to find a dose that controls the c…

This study tests whether adding a new drug (iberdomide) to an existing treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has come back or stopped responding. About 88 adults with this blood cancer will receive either the new co…

This early-stage study tests a new treatment called BCMA-CD19 cCAR for people with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target two proteins on cancer cells…

This study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…

This study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive a drug called talquetamab to help control the cancer, followed by a one-time infusion of their own modified immune cells (ci…

This study is testing a three-drug combination (MeziKD) for adults with multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. The goal is to see if this combination can shrink these tumors and contro…

This study tests whether a personalized exercise program (aerobic and resistance training) done before CAR-T therapy can improve physical fitness and quality of life in adults aged 60 and older with multiple myeloma that has returned or not responded to treatment. About 20 partic…

This study tests if certain preventive treatments can reduce or prevent taste changes caused by the drug talquetamab in people with multiple myeloma. About 210 participants will be randomly assigned to different preventive strategies. The goal is to improve quality of life by min…